Sapien Biosciences, a biotech venture backed by Apollo Hospitals, has entered into a collaboration with Bangalore-based diagnostic start-up OncoStem Diagnostics for the development and validation of a novel breast cancer recurrence prediction test.
OncoStem has developed a unique panel of 'prognostic and predictive' proteomic markers that is indicative of the aggressiveness of the cancer and hence enables prediction of the risk of recurrence within the first five years of initial diagnosis, according to an Apollo Hospitals statement.
"These markers are now being validated using retrospective tumor samples diagnosed with Stage 1, 2 or 3A breast cancer. OncoStem is collaborating with Sapien to validate this test using such annotated tumor samples with associated treatment and outcomes.
"Once the test is validated, OncoStem and Sapien will pilot and commercialise this test across the Apollo network," it added.
